ArticleJournal of immunology (Baltimore, Md. : 1950)2014
Mucosal polyinosinic-polycytidylic acid improves protection elicited by replicating influenza vaccines via enhanced dendritic cell function and T cell immunity.
Article in Journal of immunology (Baltimore, Md. : 1950), 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 47 citations in OpenAlex.
- Synthetic double-stranded RNA in antiviral immunity and vaccine adjuvant: insights into poly(I:C) and poly(A:U).Frontiers in immunology · 2026Review
- Intranasal vaccines adjuvanted with Nexavant demonstrate robust protective efficacy by inducing both mucosal and systemic immunity in a murine model.Frontiers in immunology · 2025Article
- Intranasal bovine β-defensin-5 enhances antituberculosis immunity in a mouse model by a novel protein-based respiratory mucosal vaccine.Virulence · 2022Article
- COVID-19 vaccine development based on recombinant viral and bacterial vector systems: combinatorial effect of adaptive and trained immunity.Journal of microbiology (Seoul, Korea) · 2022Review
- Protective efficacy of intranasal inactivated pseudorabies vaccine is improved by combination adjuvant in mice.Frontiers in microbiology · 2022Article
- Using Adjuvants to Drive T Cell Responses for Next-Generation Infectious Disease Vaccines.Vaccines · 2021Review
- Combination of Immunotherapy and Radiotherapy for Recurrent Malignant Gliomas: Results From a Prospective Study.Frontiers in immunology · 2021Article
- Severe Human Lassa Fever Is Characterized by Nonspecific T-Cell Activation and Lymphocyte Homing to Inflamed Tissues.Journal of virology · 2020Article
- Immune responses during COVID-19 infection.Oncoimmunology · 2020Review
- A Live Attenuated Influenza Vaccine Elicits Enhanced Heterologous Protection When the Internal Genes of the Vaccine Are Matched to Those of the Challenge Virus.Journal of virology · 2020Article
- A Testimony of the Surgent SARS-CoV-2 in the Immunological Panorama of the Human Host.Frontiers in cellular and infection microbiology · 2020Review
- Article
- Role of Type I Interferons on Filovirus Pathogenesis.Vaccines · 2019Review
- Development of Drugs Based on High-Polymeric Double-Stranded RNA for Antiviral and Antitumor Therapy.Biochemistry (Moscow) Supplement. Series B, Biomedical chemistry · 2019Article
- "Gnothi Seauton": Leveraging the Host Response to Improve Influenza Virus Vaccine Efficacy.Vaccines · 2018Review
- Marburg virus-like particles by co-expression of glycoprotein and matrix protein in insect cells induces immune responses in mice.Virology journal · 2017Article
- Monocyte-derived dendritic cells enhance protection against secondary influenza challenge by controlling the switch in CD8European journal of immunology · 2017Article
- Combination of poly I:C and Pam3CSK4 enhances activation of B cells in vitro and boosts antibody responses to protein vaccines in vivo.PloS one · 2017Article
- Chimeric Mice with Competent Hematopoietic Immunity Reproduce Key Features of Severe Lassa Fever.PLoS pathogens · 2016Article
- Influenza B virus-specific CD8+ T-lymphocytes strongly cross-react with viruses of the opposing influenza B lineage.The Journal of general virology · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 2 countries.
Funding
Abstract
Live-attenuated influenza vaccines (LAIVs) have the potential to generate CD8 T cell immunity that may limit the virulence of an antigenically shifted influenza strain in a population lacking protective Abs. However, current LAIVs exert limited T cell immunity restricted to the vaccine strains. One approach to improve LAIV-induced T cell responses is the use of specific adjuvants to enhance T cell priming by respiratory dendritic cells, but this hypothesis has not been addressed. In this study, we assessed the effect of the TLR3 ligand polyinosinic-polycytidylic acid (poly IC) on CD8 T cell immunity and protection elicited by LAIVs. Mucosal treatment with poly IC shortly after vaccination enhanced respiratory dendritic cell function, CD8 T cell formation, and production of neutralizing Abs. This adjuvant effect of poly IC was dependent on amplification of TLR3 signaling by nonhematopoietic radioresistant cells and enhanced mouse protection to homosubtypic, as well as heterosubtypic, virus challenge. Our findings indicate that mucosal TLR3 ligation may be used to improve CD8 T cell responses to replicating vaccines, which has implications for protection in the absence of pre-existing Ab immunity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.